Baird Analyst Continues to Recommend Shares of Pharmasset (VRUS); Company Remains in Catalyst-Rich, Potentially Value-Creating Period
Tweet Send to a Friend
Baird maintains an 'Outperform' rating on Pharmasset (NASDAQ: VRUS), raises PT by $1 to $54.
Baird analyst says, "Continue to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "Continue to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
